Former Incyte CEO Buys Slumping Nektar Shares
https://finance.yahoo.com/m/8c419ae4-7e72-35c6-95e9-5cbd4431…
Roy A. Whitfield, Nektar Therapeutics (NKTR) director, and former chairman and chief executive of Incyte (INCY), bought $290,200 in Nektar shares last week, buying as the biotech’s shares show weakness.
Whitfield bought 5,000 shares for his personal account over June 5 and 6, paying $58.04 each on average, he disclosed in a regulatory filing. He now owns 177,000 Nektar shares directly and 20,000 more shares through a family trust.
Continued…
Dominic
Long NKTR